Navigation Links
Clarient Launches Insight® Dx Mammostrat® Breast Cancer Recurrence Test
Date:12/9/2010

said Clarient Vice Chairman and Chief Executive Officer Ron Andrews. "Mammostrat results can provide clinicians important information to help select the appropriate therapeutic management for each individual patient. For patients, Mammostrat offers the confidence that the decisions being made to manage their breast cancer are based on the clinical characteristics of their specific disease using the most current validated technology available."

More than 210,000 women in the U.S. develop breast cancer each year. Mammostrat test development was targeted to breast tumors which express estrogen receptor, the most commonly identified subtype of breast cancer representing about 75 percent of the women diagnosed each year. The standard of care for most of these patients includes surgery to remove the tumor, followed by anti-hormonal therapy (e.g. tamoxifen or aromatase inhibitors).

Andrews continued, "Mammostrat fits well within the combined Clarient goals of bringing value to both the patient and to the healthcare system.  The test provides validated information more rapidly than other tests currently available, which may allow for treatment to begin earlier in the course of the disease."

Clarient is currently in coverage determination discussions with both government and private insurance carriers. Patents covering the use of the Mammostrat test were granted in the U.S. and Europe in the summer of 2010.

For more information on the Mammostrat test, please visit www.clarientinc.com/mammostrat.aspx.  

About ClarientClarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer.  Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care.  Clarie
'/>"/>

SOURCE Clarient, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.
2. Clarient Acquires Applied Genomics, Inc.
3. Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
4. Clarient Announces CFO Transition Plan
5. Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
6. CareFusion Launches Respiratory Airway Adapter to Improve Patient Safety and Reduce Hospital Costs
7. UBM TechInsights Launches Product Teardowns for Medical Electronics
8. Purdue Pharma L.P. Re-launches Partners Against Pain Website
9. CareFusion Launches Next-Generation Clinical Pulmonary and Cardiopulmonary Diagnostics Software
10. BugLab Launches Worlds First Handheld Non-invasive Optical Density Sensor
11. The Citizen CPR Foundation Launches National Call to Action to Empower Citizens to Save Lives of Those with Sudden Cardiac Arrest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 21, 2014   Royal Philips (NYSE: ... it has received 510(k) clearance from the U.S. ... planning application for Transcatheter Aortic-Valve Implantation (TAVI) treatments. ... interventionalists with pre-procedural, high-precision positioning to treat aortic ... application is available as part of Philips ...
(Date:8/21/2014)... 2014 Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a ... medicine, announced today the appointments of Andrew ("Andy") Arno ... Board of Directors. With these additions, the Asterias Board ... are independent. Andy Arno , 55, ... companies. He is currently Managing Director of Emerging Growth ...
(Date:8/20/2014)... Aug. 20, 2014  The National Association of ... results achieved by the real-time, pseudoephedrine (PSE) blocking ... Precursor Log Exchange (NPLEx), automatically blocks unlawful PSE ... meth offenders and make arrests. Data released by ... blocked the sale of more than ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 2Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 3Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 4Indiana's Stop-Sale System Achieves Significant Results In Battle Against Meth 2
... a healthcare investment firm with offices in Palo Alto, ... of Vivo Ventures VII ("Vivo VII") at $375 million, ... more than $1 billion. Vivo plans ... pharmaceutical and medical device companies in the U.S. and ...
... Therapeutics, Inc. (NASDAQ: ECTE ), a ... a non-invasive, wireless, transdermal continuous glucose monitoring system ... delivery, today announced that Patrick T. Mooney, M.D., ... at the Biotech Showcase 2012 Conference. ...
Cached Medicine Technology:Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China 2Echo Therapeutics to Present at Biotech Showcase 2012 in San Francisco 2
(Date:8/22/2014)... For the fourth time, TharpeRobbins, a global leader ... received a prestigious level of recognition from Inc. Magazine. ... remains on the exclusive list of top 5000 fastest ... the list in 2010, 2011 and 2013. , ... list for a fourth time," says Brett Tharpe, CEO ...
(Date:8/22/2014)... Omaha, NE (PRWEB) August 22, 2014 ... has once again earned a position on the Inc. ... healthcare staffing company placed in position 1424 on the ... revenue of $126.2 million. This marks the seventh time ... earned a spot on the Inc. 5000, including one ...
(Date:8/22/2014)... Kicking blog MichaelHusted.com is featuring an interview ... his role as a kicking coach, his kicking business, and ... retired NFL kicker Michael Husted author of Husted Kicking.com. , ... him join our NCS Network,” says Husted. “He brings a ... will continue to strengthen our coaching staff and the NCS ...
(Date:8/22/2014)... 2014 An increasing number of mergers ... in the market. M&As provide financial assistance to smaller ... rise the distribution channels of companies and help in ... markets. , According to the “ Global Animal Health ... and protein-rich diet is one of the major drivers ...
(Date:8/22/2014)... 2014 AttorneyOne.com, a recognized authority on ... information from the FDA on Diamondback 360 Peripheral ... announced on August 19, that certain lots of the ... (Part number 7-10003), by Cardiovascular Systems, are recalled ... could fracture during use and could possibly block blood ...
Breaking Medicine News(10 mins):Health News:For The Fourth Time - TharpeRobbins Earns A Place On Prestigious Inc. Magazine 500|5000 List 2Health News:For The Fourth Time - TharpeRobbins Earns A Place On Prestigious Inc. Magazine 500|5000 List 3Health News:Medical Solutions Earns Position on the 2014 Inc. 5000 List 2Health News:MichaelHusted.com Interviews Coach Brian Jackson of Team Jackson Kicking on His Role as a Kicking Coach, and on Becoming a National Camp Series (NCS) Associate 2Health News:MichaelHusted.com Interviews Coach Brian Jackson of Team Jackson Kicking on His Role as a Kicking Coach, and on Becoming a National Camp Series (NCS) Associate 3Health News:Global Animal Health Market 2014-2018 a New Research Report Added to ReportsnReports.com 2Health News:Global Animal Health Market 2014-2018 a New Research Report Added to ReportsnReports.com 3Health News:Global Animal Health Market 2014-2018 a New Research Report Added to ReportsnReports.com 4Health News:Diamondback 360 Peripheral Orbital Atherectomy System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2
... in an extremely exciting phase right now. We are ... formed and are starting clinical trials in different areas," ... first-in-human study was just initiated for Parkinson,s disease patients ... NeuroNova. The drug, which is administered into the fluid-filled ...
... ST. PAUL, Minn., May 21 Three HealthEast ... agreed to pay the federal government a total ... tam") lawsuit alleging Medicare fraud involving a certain ... hospitals are the first hospitals to settle charges ...
... FRANCISCO -- Mayo Clinic researchers have found that bipolar ... as diabetes, depression, asthma or coronary artery disease. These ... claim costs. Specialty care costs (the costs of seeing ... for bipolar patients. Results of this review are being ...
... May 21 Elimination of funding for ... by the Senate Republican budget plan would end a ... rate of health care cost increases, improving quality of ... today.For the past two years the small "think tank" ...
... HMS today announced that it had been awarded contracts ... million lives to the company,s portfolio. HMS will be providing ... party recovery and cost avoidance -- to Citrus Health Care, ... (NY); Health First (NY); Health Plan of Michigan, Inc. (MI); ...
... (May 21, 2009) In comparing ultrasound with other medical ... review of published studies in the May/June issue of ... of ultrasound to provide an accurate diagnosis more cost ... the 1950s, ultrasound has been utilized mostly in hospital settings. ...
Cached Medicine News:Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 2Health News:Minnesota Hospitals Pay $2.28 Million to Settle Medicare Fraud Charges Involving Kyphoplasty 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 2Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 3Health News:Senate Republican Budget Would End Health Initiatives That Save Lives and Money 4
... The unique triple-mode technology ... all-around system for an array ... technology includes a patented, controllable ... mode for classical ablation procedures, ...
... Test is the only in-office test approved by ... The NMP22 BladderChek Test is a painless and ... that detects elevated levels of NMP22 protein. Healthy ... protein in the urine. However, the level of ...
ARION is a long-pulsed alexandrite laser system with a wavelength of 755 nm...
Used for measuring rectal pressure during urodynamic studies. All-silicone construction provides maximum softness and biocompatibility for enhanced patient comfort. Supplied sterile in peel-open pack...
Medicine Products: